|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
April 2005FeaturesCover Story Payers’ Dilemma: Looming Costs for Chronic ConditionsBiotech products for chronic conditions will be coming with regularity in the next few years, and these represent both a clinical opportunity and a financial challenge for health plans. So far, few payers have figured out how to make such treatments available without breaking the bank. Strategies Biologics’ Looming Price Tag Has Payers Retooling Pharmacy CoverageWith more biologics for chronic conditions becoming available in the next few years, managed care plans face the issues of whether and how to cover
such treatments. Prudent plans are shaping their strategies now, so they’ll be ready when the big biologics wave hits. Diagnostics Bio Bets Its Chips on Better OutcomesWith the proliferation of DNA chips picking up speed, the pharmacogenomics revolution is closer than ever. When Silicon Valley meets biotech, the result is personalized medicine. But who gets access to these high-tech tools? Innovation University Technology Transfer Offices: A Status ReportTransferring discoveries and innovations from academia to the business sector can be a tricky yet profitable business that serves the public good. Where does the funding come from, where is it going, and what sorts of issues threaten relations between universities and private industry? Leading Edge When Time Is of the Essence.Makers of simple rapid tests that quickly diagnose influenza without compromising safety are striving to find a niche with health plans that must decide whether the cost of treating the flu bug is worth the expense. The market for rapid testing is expected to mushroom in 5 to 10 years. DepartmentsOpeners The Tale of the TapeA more sophisticated industry. Editorial Open-Source ScienceDavid B. Nash, MD, MBA, discusses the potential role of open-source science. Discourse What if CMS Threw a Party, But Nobody Came?What’s behind enrollment figures for a test run of Medicare Part D? Marking the Progress of Genetic TestingHow far has genetic testing come? Biotech Business Report Portrays Nanotechnology as Driver of Reduced R&D Costs
Amanda Brower Corporate Spotlight The Medicare Part D Benefit: Preventing Drug Coverage Disruption for Enrollees in the Replacement Drug DemoLessons from the Section 641 demo. In the Pipeline U.S. Biotech Climate Strongest in EastEastern states lead in innovation. |
|||||